超越粉样质斑块,在阿尔茨海默病中准α-synuclein:战斗仍在继续
Hayder M Al-Kuraishy1, Ghassan M Sulaiman2, Hamdoon A Mohammed3
1Department of Clinical pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad 14022, Iraq.
Ageing research reviews
|February 6, 2025
概括
通常与帕金森病相关的α-synuclein (α-Syn) 聚合物可能在阿尔茨海默病 (AD) 神经病理学中发挥作用. 准这些α-Syn聚合物可能为治疗AD提供新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 痴呆症研究 痴呆症研究
背景情况:
- 阿尔茨海默病 (AD) 是一种常见的神经退行性疾病,导致认知障碍和记忆丧失.
- 阿尔茨海默病理包括突触功能障碍,粉样β (Aβ) 斑块和神经纤维细胞结 (NFT).
- 其他错误折叠的蛋白质,如α-synuclein (α-Syn),越来越多地与复杂的神经退行性疾病有关.
研究的目的:
- 探索阿尔茨海默病 (AD) 中α-synuclein (α-Syn) 的病理作用.
- 调查针对α-Syn聚合物的潜力,作为AD治疗方法.
主要方法:
- 本综述综合了关于AD中α-Syn的现有研究.
- 它研究了α-Syn聚合和AD神经病理学之间的联系.
主要成果:
- 阿尔法-同核素 (α-Syn) 涉及到AD神经病理学,超出其在帕金森病 (PD) 中已知的作用.
- 在AD病变发生过程中α-Syn的确切作用需要进一步阐明.
- 有证据表明α-Syn聚合有助于AD的突触功能障碍.
结论:
- α-synuclein (α-Syn) 聚合是阿尔茨海默病 (AD) 病理学的潜在贡献者.
- 向α-Syn聚合物为AD治疗提供了一个有前途的治疗途径.
- 需要进一步的研究,以充分理解和利用针对阿尔茨海默病的α-Syn治疗潜力.
相关概念视频
Alzheimer's Disease: Treatment
158
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
158
Alzheimer's Disease: Overview
437
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
437


